130 related articles for article (PubMed ID: 2955818)
21. Dye-mediated photolysis of human neuroblastoma cells: implications for autologous bone marrow transplantation.
Sieber F; Rao S; Rowley SD; Sieber-Blum M
Blood; 1986 Jul; 68(1):32-6. PubMed ID: 3521764
[TBL] [Abstract][Full Text] [Related]
22. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma.
Broxmeyer HE; Williams DE; Lu L; Cooper S; Anderson SL; Beyer GS; Hoffman R; Rubin BY
J Immunol; 1986 Jun; 136(12):4487-95. PubMed ID: 3086433
[TBL] [Abstract][Full Text] [Related]
23. Purging of small cell lung cancer cells from human bone marrow using ethiofos (WR-2721) and light-activated merocyanine 540 phototreatment.
Meagher RC; Rothman SA; Paul P; Koberna P; Willmer C; Baucco PA
Cancer Res; 1989 Jul; 49(13):3637-41. PubMed ID: 2543500
[TBL] [Abstract][Full Text] [Related]
24. Differential killing of murine B-cell leukemia (BCL1) by photosensitization with merocyanine 540: implications for autologous bone marrow transplantation.
Mumcuoglu M; Weiss L; Spivak J; Slavin S
Bone Marrow Transplant; 1989 Mar; 4(2):143-6. PubMed ID: 2650782
[TBL] [Abstract][Full Text] [Related]
25. TGF-beta 3 protects normal human hematopoietic progenitor cells treated with 4-hydroperoxycyclophosphamide in vitro.
Lemoli RM; Strife A; Clarkson BD; Haley JD; Gulati SC
Exp Hematol; 1992 Dec; 20(11):1252-6. PubMed ID: 1493854
[TBL] [Abstract][Full Text] [Related]
26. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells.
Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Rizzoli V
Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: preclinical studies.
Motta MR; Mangianti S; Rizzi S; Ratta M; Campanini E; Fortuna A; Fogli M; Tura S; Lemoli RM
Exp Hematol; 1997 Nov; 25(12):1261-9. PubMed ID: 9357970
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological elimination of tumor cells contaminating normal human bone marrow using PTT-119.
Lemoli RM; Gulati SC; Perez A; Clarkson BD
Cancer Commun; 1990; 2(2):87-91. PubMed ID: 2196924
[TBL] [Abstract][Full Text] [Related]
29. Effects of in vivo treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on proliferation kinetics of bone marrow and blood myeloid progenitor cells in patients with sarcoma.
Broxmeyer HE; Benninger L; Cooper S; Hague N; Benjamin RS; Vadhan-Raj S
Exp Hematol; 1995 Apr; 23(4):335-40. PubMed ID: 7895781
[TBL] [Abstract][Full Text] [Related]
30. Predictive value of colony-forming unit assays for engraftment and leukemia-free survival after transplantation of chemopurged syngeneic bone marrow in rats.
Wiley JM; Yeager AM
Exp Hematol; 1991 Mar; 19(3):179-84. PubMed ID: 1704843
[TBL] [Abstract][Full Text] [Related]
31. Role of cytoprotective mechanisms in the photochemical purging of autologous bone marrow grafts.
Yamazaki T; Sato Y; Sieber F
Exp Hematol; 1997 Jul; 25(7):629-37. PubMed ID: 9216739
[TBL] [Abstract][Full Text] [Related]
32. Effect of the Cdk-inhibitor roscovitine on mouse hematopoietic progenitors in vivo and in vitro.
Song H; Vita M; Sallam H; Tehranchi R; Nilsson C; Sidén A; Hassan Z
Cancer Chemother Pharmacol; 2007 Nov; 60(6):841-9. PubMed ID: 17318617
[TBL] [Abstract][Full Text] [Related]
33. Photochemical purging of autologous bone marrow grafts: assessment of damage to stem cells and the microenvironment in long-term marrow cultures.
Kubo Y; Sieber F
Bone Marrow Transplant; 1997 Jul; 20(1):27-31. PubMed ID: 9232252
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
[TBL] [Abstract][Full Text] [Related]
35. GM-CSF therapy for delayed engraftment after autologous bone marrow transplantation.
Brandwein JM; Nayar R; Baker MA; Sutton DM; Scott JG; Sutcliffe SB; Keating A
Exp Hematol; 1991 Mar; 19(3):191-5. PubMed ID: 1995310
[TBL] [Abstract][Full Text] [Related]
36. Comparative regimens for the ex vivo chemopurification of B cell lymphoma-contaminated marrow.
Gulati SC; Atzpodien J; Langleben A; Shimazaki C; Jain K; Yopp J; Ng RP; Colvin OM; Clarkson BD
Acta Haematol; 1988; 80(2):65-70. PubMed ID: 2458665
[TBL] [Abstract][Full Text] [Related]
37. Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults.
Broxmeyer HE; Hangoc G; Cooper S; Ribeiro RC; Graves V; Yoder M; Wagner J; Vadhan-Raj S; Benninger L; Rubinstein P
Proc Natl Acad Sci U S A; 1992 May; 89(9):4109-13. PubMed ID: 1373894
[TBL] [Abstract][Full Text] [Related]
38. Human chemokines: enhancement of specific activity and effects in vitro on normal and leukemic progenitors and a factor-dependent cell line and in vivo in mice.
Broxmeyer HE; Cooper S; Hague N; Benninger L; Sarris A; Cornetta K; Vadhan-Raj S; Hendrie P; Mantel C
Ann Hematol; 1995 Nov; 71(5):235-46. PubMed ID: 7492626
[TBL] [Abstract][Full Text] [Related]
39. Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures.
La Russa VF; Griffin JD; Kessler SW; Cutting MA; Knight RD; Blattler WA; Lambert JM; Wright DG
Exp Hematol; 1992 May; 20(4):442-8. PubMed ID: 1373688
[TBL] [Abstract][Full Text] [Related]
40. Differential cytotoxicity of an ether lipid on lymphoma and bone marrow cells and its role in purging malignant lymphoid cells from remission bone marrow contaminated with tumor cells.
Dietzfelbinger HF; Lang A; Oberberg D; Rastetter JW; Berdel WE
Exp Hematol; 1992 Feb; 20(2):178-83. PubMed ID: 1544386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
